Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Beck Peccoz

Showing results (181-190 of 201) with videos related to

Pageof 21
Sort By:
The Journal of Clinical Endocrinology and Metabolism|October 22, 2010
GH response to oral glucose tolerance test: a comparison between patients with acromegaly and other pituitary disordersE Verrua, M Filopanti, C L Ronchi, et al.
Journal of Endocrinological Investigation|February 6, 2017
Long-term safety and efficacy of Omnitrope<sup>®</sup> in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults studyD Ferone, E Profka, V Gasco, et al.
European Journal of Endocrinology|November 13, 2013
Impact of IGF(CA)19 gene polymorphism on the metabolic response to GH therapy in adult GH-deficient patientsC Giavoli, E Profka, E Sala, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|October 9, 2009
Evaluation of GH-IGF-I axis in adult patients with coeliac diseaseE Ferrante, C Giavoli, L Elli, et al.
Journal of Endocrinological Investigation|March 15, 2005
Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomasM Filopanti, E Ballarè, A G Lania, et al.
The Journal of Clinical Endocrinology and Metabolism|April 19, 2000
Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotideJ M Kuhn, S Arlot, H Lefebvre, et al.
Clinical Endocrinology|June 9, 2007
Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal studyC L Ronchi, M Boschetti, E C Degli Uberti, et al.
European Journal of Endocrinology|September 17, 2009
Peripheral insulin-like factor 3 concentrations are reduced in men with type 2 diabetes mellitus: effect of glycemic control and visceral adiposity on Leydig cell functionF Ermetici, F Donadio, L Iorio, et al.
European Journal of Endocrinology|March 15, 2001
Two familial giant pituitary adenomas associated with overweight: clinical, morphological and genetic featuresE Ferretti, M L Jaffrain Rea, C Asteria, et al.
Clinical Endocrinology|February 27, 2010
Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspectsV Morelli, B Masserini, A S Salcuni, et al.
Pageof 21

Showing results (181-190 of 201) with videos related to

Sort By:
Pageof 21
The Journal of Clinical Endocrinology and Metabolism|October 22, 2010
GH response to oral glucose tolerance test: a comparison between patients with acromegaly and other pituitary disordersE Verrua, M Filopanti, C L Ronchi, et al.
Journal of Endocrinological Investigation|February 6, 2017
Long-term safety and efficacy of Omnitrope<sup>®</sup> in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults studyD Ferone, E Profka, V Gasco, et al.
European Journal of Endocrinology|November 13, 2013
Impact of IGF(CA)19 gene polymorphism on the metabolic response to GH therapy in adult GH-deficient patientsC Giavoli, E Profka, E Sala, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|October 9, 2009
Evaluation of GH-IGF-I axis in adult patients with coeliac diseaseE Ferrante, C Giavoli, L Elli, et al.
Journal of Endocrinological Investigation|March 15, 2005
Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomasM Filopanti, E Ballarè, A G Lania, et al.
The Journal of Clinical Endocrinology and Metabolism|April 19, 2000
Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotideJ M Kuhn, S Arlot, H Lefebvre, et al.
Clinical Endocrinology|June 9, 2007
Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal studyC L Ronchi, M Boschetti, E C Degli Uberti, et al.
European Journal of Endocrinology|September 17, 2009
Peripheral insulin-like factor 3 concentrations are reduced in men with type 2 diabetes mellitus: effect of glycemic control and visceral adiposity on Leydig cell functionF Ermetici, F Donadio, L Iorio, et al.
European Journal of Endocrinology|March 15, 2001
Two familial giant pituitary adenomas associated with overweight: clinical, morphological and genetic featuresE Ferretti, M L Jaffrain Rea, C Asteria, et al.
Clinical Endocrinology|February 27, 2010
Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspectsV Morelli, B Masserini, A S Salcuni, et al.
Pageof 21